Physician profile
Amy E Barras
NPI 1730854613
$2,785.71
in general payments reported to CMS, 2019-2025
22 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.33 · 2022: $798 · 2023: $893 · 2024: $740 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,906.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,020.21 | 2021-2025 | |
| Novo Nordisk INC | $424.06 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $371.99 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $209.06 | 2022 | |
| Amgen INC. | $114.32 | 2021-2025 | Tezspire, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $107.61 | 2021-2024 | Farxiga |
| Lilly USA, LLC | $106.08 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Organon LLC | $67.53 | 2022-2024 | Nexplanon |
| Boston Scientific Corporation | $56.65 | 2025 | General - Pain Management |
| Regeneron Healthcare Solutions, INC. | $50.46 | 2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $32.27 | 2024 | |
| Merck Sharp & Dohme LLC | $30.20 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Lundbeck LLC | $25.61 | 2024 | Rexulti |
| Ars Pharmaceuticals Operations, INC. | $25.16 | 2025 | Neffy |
| Gilead Sciences, INC. | $22.08 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $21.35 | 2024 | Ingrezza |
| Exact Sciences Corporation | $20.77 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $19.44 | 2023 | Xarelto |
| Mylan Specialty L.P. | $17.10 | 2022 | |
| Metacel Pharmaceuticals LLC | $15.03 | 2023 | Ozobax |
| Axsome Therapeutics, INC. | $14.57 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.16 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Barras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.